Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register
Brain and Behavior · 2025
DOI: 10.1002/brb3.70326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Henrik Ahvenjärvi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Immunologic Factors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Finnish Cultural Foundation, The Finnish Neurological Society, the University of Oulu Scholarship Foundation.
Abstract (Originalsprache)
Background
The treatment of relapsing‐remitting multiple sclerosis (RRMS) is changing. There are limited data about initial treatment of RRMS in Finland.
Objective
Our objectives were to study the trends of initial disease‐modifying treatments (DMTs) for patients with RRMS from 2013 to 2022, treatment delays, factors associated with DMT choice, DMT switch patterns, and the effect of the COVID‐19 pandemic.
Methods
This retrospective register study used secondary data from the Finnish MS register. The DMTs were classified into medium‐efficacy DMTs (meDMTs; beta interferons, glatiramer acetate, fumarates, and teriflunomide) and high‐efficacy DMTs (heDMTs; alemtuzumab, cladribine, daclizumab, natalizumab, ocrelizumab, ofatumumab, and rituximab).
Results
The inclusion criteria were fulfilled by 2479 individuals. From 2013 to 2022, the proportion of heDMTs as the initial therapy increased by 5.3‐fold from 6.9% to 43.7% ( p < 0.001). Median diagnostic delay decreased from 10.1 to 4.6 months ( p < 0.001). The COVID‐19 pandemic did not cause treatment delays. Higher disease activity and younger age were associated with the choice of heDMT as the initial DMT. heDMTs were the preferred second DMT in patients switching due to lack of efficacy.
Conclusion
In Finland, the treatment of RRMS has shifted toward earlier diagnosis and earlier initiation of heDMTs, likely improving the prognosis of the patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland.
- Novartis Finland Ltd, Espoo, Finland.
- StellarQ Ltd, Turku, Finland.
- Medical Research Center, Oulu University Hospital, Oulu, Finland.
- Clinical Neurosciences, University of Helsinki, Helsinki, Finland.
- Clinical Neurosciences, University of Turku, Turku, Finland.
ORCID-Profile: Henrik Ahvenjärvi, Merja Soilu-Hänninen
Förderung
- The Finnish Cultural Foundation
- The Finnish Neurological Society
- the University of Oulu Scholarship Foundation
- the Finnish MS Foundation
- Novartis Finland Ltd
Zitieren
APA
Ahvenjärvi, H., Jokinen, E., Viitala, M., Autio, H., Portaankorva, A. M., Soilu-Hänninen, M., Krüger, J., & Ryytty, M. (2025). Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register. Brain and Behavior. https://doi.org/10.1002/brb3.70326
Vancouver
Ahvenjärvi H, Jokinen E, Viitala M, Autio H, Portaankorva AM, Soilu-Hänninen M, et al. Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register. Brain and Behavior. 2025. doi:10.1002/brb3.70326
BibTeX
@article{Ahvenjrvi2025,
author = {Ahvenjärvi, Henrik and Jokinen, Elina and Viitala, Matias and Autio, Henri and Portaankorva, Anne M and Soilu-Hänninen, Merja and Krüger, Johanna and Ryytty, Mervi},
title = {Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70326}
}
EUVIMED